OP18 – Reduction of the endogenous ligands for peroxisome proliferator-activated receptor gamma in papillary thyroid cancer
Other conference paper


其它資訊
摘要Background/Purpose/Objectives: Increasing evidence indicates a role of peroxisome
proliferator-activated receptor gamma (PPAR?) in the proliferation and growth of papillary
thyroid cancer (PTC). PPAR? usually needs to be activated by its ligands before it exerts the
inhibitory effect on tumor cells. The objective of this study was to examine the status of
endogenous ligands that has not been investigated in thyroid cancer.
Methods: We isolated the lysates of PTC tumor tissues and then measure the levels of 3
main endogenous ligands, 15-deoxy-?(12,14)-prostaglandin J2 (15d-PGJ2), 13-Shydroxyoctadecadienoic
acid (13(S)-HODE) and 15(S)-hydroxyeicosatetraenoic acid (15(S)
-HETE) using ELISA method. We also attempted to alter the levels of these ligands to check
whether they would affect the survival/death of PTC cells.
Results: The levels of these 3 endogenous ligands, 15(S)-HETE in particularly, were
significantly reduced in tumor tissues of PTC compared with non-tumor thyroid tissues
(p<0.01). In the cultured PTC cells (K1 and BCPAP), we found that the levels of these 3
ligands could be obviously increased by inhibiting estrogen receptor alpha (ERa) or
activating estrogen receptor beta (ERb). Accompanied the upregulation of these ligands,
the survival of PTC cells was reduced but the apoptosis was enhanced.
Discussion & Conclusion: We have demonstrated that PTC is associated with reduced
levels of endogenous PPAR? ligands and that the upregulation of the endogenous ligands,
which are generally believed to be well tolerated and nontoxic, can promote the death of
PTC cells.
著者Chen George G, Wang Sangsang, Ho Jessica WM, Vlantis Alexander C, Liu Shirley YW, Ng Enders KW, Ng Siu Kwan, Van Hasselt Andrew C, Tong Michael CF.
會議名稱3rd World Congress on Thyroid Cancer
會議開始日27.07.2017
會議完結日30.07.2017
會議地點Boston
會議國家/地區美國
出版年份2017
語言美式英語

上次更新時間 2018-07-05 於 11:08